Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Philogen SpA ( (IT:PHIL) ) is now available.
Philogen S.p.A. reported its half-year financial results for 2025, showing a significant increase in revenue from contracts with customers, driven by a new contract with RayzeBio. Despite a negative net result, the company’s financial position remains strong, supported by liquidity and expected milestones from license agreements. The company is progressing with its regulatory submissions for Nidlegy™ and advancing clinical trials for various cancer treatments, indicating a robust pipeline and long-term sustainability.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen S.p.A. operates in the biotechnology industry, focusing on the development of targeted therapies for cancer and other diseases. The company, along with its Swiss subsidiary Philochem, is involved in the research and development of a diversified pipeline of products ranging from preclinical to Phase III clinical studies. Philogen’s market focus includes advancing its drug candidates towards registration and continuing discovery activities to create new therapies.
Average Trading Volume: 19,820
Technical Sentiment Signal: Buy
Current Market Cap: €672.6M
For detailed information about PHIL stock, go to TipRanks’ Stock Analysis page.